LG Chem, Ltd

Knowledge

FOTIVDA® (Tivozanib)

Product Profile

Apply for Sample

CAS Formula HS Code Database – FOTIVDA® (Tivozanib)

Product Identification

Aspect Industrial Commentary
Product Name FOTIVDA®
IUPAC Name 1-[(6,7-dimethoxy-4-quinolyl)oxy]-3-{[2-(methylamino)ethyl]carbamoyl}indole-2-carboxamide
Chemical Formula C22H19N5O4
Synonyms & Trade Names Tivozanib, AV-951
CAS Number 475108-18-0
HS Code & Customs Classification Based on the international chemical compound scope and its pharmaceutical designation, FOTIVDA® (Tivozanib) aligns with HS Code 2933.59 for customs classification. This classification covers heterocyclic compounds with nitrogen hetero-atom(s) only, specifically other lactams and quinolines utilized in active pharmaceutical ingredient (API) scenarios. Importers and supply chain managers typically provide additional sub-codes depending on the regional regulatory and documentation environments. Entry and clearance may reference an API-specific customs description, and supporting data such as Certificate of Analysis and DMF linkage are recommended per batch for verification efficiency.

Technical Manufacturing Notes

Property Manufacturer Technical Commentary
Raw Material Selection Raw material selection requires qualification of key intermediates with defined impurity profiles. Sources must ensure traceability for all aromatic precursors and nitrogen sources. Tiered supplier audits target stability and impurity carryover, with secondary reference materials reserved for critical process revalidations or origin diversification protocols under GMP.
Process Route Rationale Process selection targets maximum yield with minimized side-product formation. Key steps focus on etherification and amide bond formation; specific catalysts and solvent grades are chosen to meet batch purity expectations and reduce by-product load. Solvent recycling and controlled crystallization steps are critical for meeting both purity and particle size specification for formulation.
Key Control Points In-process controls monitor N-alkylation and carbamoyl coupling steps for incomplete conversion residues. Analytical checkpoints monitor for residual solvents and step-specific intermediates, particularly at the post-purification and pre-release stages. Solvent duration, pH, and temperature bands depend on batch scale and equipment.
Impurity Generation and Purification Batch manufacturing can generate minor aromatic and amide decomposition products. Purification employs solid-phase extraction and multiple recrystallization cycles; typical values depend on grade. Final purity and allowable impurity content follow customer or regulatory guidelines, with process adjustments introduced when batch trends affect downstream risk assessment.
Batch Consistency & Release Each commercial batch is subject to statistically designed quality control sampling. Release criteria cover defined impurity thresholds, residual solvent limits, and assay value matching the registered specification. Detailed release standards depend on the pharmacopoeial or customer-driven criteria. Supply for regulated markets requires batch-specific Full Quality Documentation and optional stability data as negotiated per contract.

Property-Relevant Commentary

Aspect Manufacturer Technical Explanation
Grade-Dependent Properties Solid-state form, particle size distribution, and residual solvent profile vary according to API processing route and downstream formulation requirements. Micronized API may be required for specific oral dosage development, with additional controls for moisture and aggregate content. Standard and high-purity grades see differentiated acceptance criteria for trace organic and inorganic residues.
Application Sensitivity Supply for pharmaceutical development prioritizes tight controls on related substances and polymorphic purity. Formulation partners may request reanalysis or retesting under their storage simulation; project-specific stress-testing may be contractually required before release of clinical materials.
Effect on Storage, Handling, Processing Packaging in sealed, inert-atmosphere containers mitigates hydrolysis and oxidation risk. Most facilities implement temperature- and humidity-monitored storage. Batch traceability extends from drum to final packaging, reflecting pharmaceutical market compliance. Deviations in storage conditions are logged for full pharmaceutical audit traceability.

Technical Properties, Manufacturing Process & Safety Guidelines for FOTIVDA® (Tivozanib)

Physical & Chemical Properties

Physical State & Appearance

Commercially manufactured Tivozanib is usually isolated as a solid, with quality control departments checking for consistent form and color based on the selected polymorph and formulation grade. Most production routes yield a crystalline powder, off-white to pale yellow depending on minor impurities or solvates introduced during purification. Odor is not a critical identifier for this product and is not used as a release parameter. Melting point is batch-dependent and referenced to established internal standards for identification and purity. Boiling point does not provide useful guidance for this solid under normal handling conditions in the manufacturing facility. Flash point is not relevant as it is manufactured and processed in solid or solution form below temperatures of thermal decomposition.

Chemical Stability & Reactivity

Chemical stability of Tivozanib is closely managed through tight process controls and careful selection of intermediate purification steps to minimize degradation or isomerization. Reactive impurity formation, such as hydrolysis or oxidation products, is monitored by analytical means during storage trials under ICH conditions. Physical form and residual solvent content may influence degradation profile; forced degradation studies guide packaging and handling protocols.

Solubility & Solution Preparation

Solubility parameters are evaluated based on formulation requirements. Tivozanib demonstrates variable solubility across solvents, with aqueous solubility typically low and organic solvent compatibility dependent on crystalline or amorphous state. Solution preparation instructions are tailored for downstream use and specify filtration and pH adjustment where necessary to achieve complete dissolution. Grade and polymorph selection affect dissolution kinetics and filtration requirements, which factor into blending and formulation controls.

Technical Specifications & Quality Parameters

Specification Table by Grade

Specifications for Tivozanib are determined by target application and region, reflecting pharmaceutical grade or process intermediate use. Reference lots and retention samples ensure conformance across production campaigns. Key attributes—such as assay, water content, and residual solvent—are outlined in internal quality documentation, with limits aligned to customer and regulatory needs.

Impurity Profile & Limits

Manufacturing teams monitor both process-related and degradation impurities across all steps, referencing compendial and internal thresholds. Impurity limits are set according to the intended application, with medicinal use dictating the most stringent profiles. Analytical chemists utilize validated HPLC and mass spectrometry assays to locate and trend known and unknown peaks in every batch, referencing control samples of identified synthetic byproducts and degradation species.

Test Methods & Standards

Release testing and in-process controls follow established analytical protocols. Combination of compendial methods and custom-developed assays supports both identification and purity confirmation. Grade-specific adjustments are made to testing protocols to reflect regional requirements and the evolving impurity profile inherent to the synthetic route.

Preparation Methods & Manufacturing Process

Raw Materials & Sourcing

Stage gate reviews for raw material sourcing focus on traceability and impurity carryover risk. Suppliers are audited for quality management and ability to deliver consistent intermediate specifications. Batch genealogy is tracked from primary building blocks through all synthetic stages to support root cause investigation in the event of process deviation.

Synthesis Route & Reaction Mechanism

Synthetic chemists select among several known synthetic routes for Tivozanib, factoring in raw material availability, byproduct risk, yield, and scalability. Multistep synthesis protocols rely on robust intermediate isolation and purification, each step validated to monitor for side products and incomplete conversion. Mechanistic understanding, including catalysis, solvent selection, and thermal profile, drives stepwise impurity rejection and cost control.

Process Control & Purification

Process engineers implement closed-loop process controls on temperature, pH, and addition rates to maintain product quality. Washing, crystallization, and filtration steps are optimized batch-to-batch via trend analysis and statistical process control, with parameters tuned to control particle size and reduce entrapment of process impurities. Purification strategy emphasizes multi-stage crystallization and solvent exchange to maximize final grade purity and minimize carryover.

Quality Control & Batch Release

Each batch undergoes full panel release testing for identification, purity, impurity profile, and physical form. Release criteria are defined internally after review of regional and customer-specific needs. Deviations prompt full root-cause investigation, with manufacturing and quality teams collaborating on corrective and preventive action plans.

Chemical Reactions & Modification Potential

Typical Reactions

Synthetic and analytical teams observe that Tivozanib can undergo standard chemical modifications, including hydrolysis under strong acid or base, and potential oxidation in the presence of reactive oxygen species. Reaction outcomes depend on grade, form, and solution conditions.

Reaction Conditions (Catalyst, Temperature, Solvent)

Laboratory and process development setpoints for catalyst loading, temperature, and solvent selection are iteratively optimized for each campaign to balance impurity suppression, reaction yield, and process safety. Reaction windows typically align with constraints needed to avoid environmental contamination and materials incompatibility.

Derivatives & Downstream Products

Derivative research occurs under controlled development projects, with process modifications recorded. Potential for new salt forms, amorphous dispersions, or prodrugs is evaluated in scale-up studies and intellectual property reviews before any commercial run.

Storage & Shelf Life

Storage Conditions (Temperature, Humidity, Light Avoidance, Gas Protection)

Long-term storage studies confirm that temperature and humidity influence both the physical state and chemical stability of Tivozanib. Warehouses employ controlled ambient conditions, and customers receive handling recommendations tailored to the grade’s moisture sensitivity and photolability. For high-sensitivity lots, packaging design incorporates barrier films or desiccants to limit exposure.

Container Compatibility

Compatibility with primary packaging is validated through extractable and leachable studies. Material selection takes into account solvent compatibility, permeation risk, and interaction with product form. Glass, HDPE, or specific lined containers are used according to batch size and shipping method.

Shelf Life & Degradation Signs

Shelf life determination follows ICH stability protocols, with ongoing monitoring for color change, physical property shifts, and impurity growth. Specific shelf life claims depend on grade and storage conditions, and customers are advised to consult batch-specific stability data for recommended retest periods. Signs of degradation, such as off-spec impurity profiles or crystallinity loss, prompt further quality investigation.

Safety & Toxicity Profile

GHS Classification

Hazard communication sheets provide the GHS classification and applicable hazard and precautionary statements based on toxicology studies and chemical structure. Production staff receive regular training on risk management in line with these classifications.

Hazard & Precautionary Statements

Handling protocols for Tivozanib address potential risks linked with dust formation, accidental exposure, and environmental release. Production and laboratory staff follow established PPE guidelines and engineering controls to minimize inhalation and skin contact.

Toxicity Data

Toxicological evaluations reference published pharmaceutical and preclinical safety data. Process safety teams use established thresholds to assess manufacturing occupational exposure and guide process containment selection. Cleaning validation targets direct risk reduction of cross-contamination within multipurpose plants.

Exposure Limits & Handling

Standard operating procedures reflect both industry consensus and regulatory submission history for exposure control, release thresholds, and emergency response. Manufacturing environments utilize robust ventilation and containment practices, with personal monitoring programs to ensure exposure remains within internal control limits based on current knowledge and ongoing assessment.

FOTIVDA® (Tivozanib) – Supply Capacity, Commercial Terms & 2026 Price Trend Forecast

Supply Capacity & Commercial Terms

Production Capacity & Availability

Current production of FOTIVDA® (Tivozanib) operates on a campaign basis using multi-purpose synthesis lines dedicated to oncology APIs. Output is driven by orders from major market authorisation holders. Production slot allocation fluctuates, depending on the length and complexity of each synthesis step, quality control requirements for high-purity oncology actives, and scheduling between other priority projects. Robust forward planning from pharmaceutical partners is necessary to ensure uninterrupted supply; back orders commonly reflect both surge demand and tighter GMP compliance.

Lead Time & MOQ (Minimum Order Quantity)

Expected lead times move between 12 and 20 weeks, heavily contingent on both availability of GMP grade key starting materials and the degree of analytical release testing needed by client dossiers. Lower-volume requests (especially for clinical development) sometimes face longer waits since full production typically prioritizes commercial-scale batch sizes. MOQ hinges on the grade, but routinely matches the minimum campaign batch size configured for validated reactor capacity. Smaller pilot or validation orders require special assessment by production heads.

Packaging Options

Standard packaging utilizes dual PE-lined fiber drums or HDPE containers, fitted with tamper-evident closures, protective foil liners, and inert gas purging where demanded by sensitivity assays. The packaging configuration adjusts if a particular registration country defines import packaging protocols. For highly moisture- or oxygen-sensitive forms, vacuum-sealed bags inside rigid drums lower peroxide or degradation risk during transit and storage; custom packaging is prepared against customer import release stipulations.

Shipping & Payment Terms

Our logistics protocols restrict scheduling to validated GDP partners with explicit ADR/ICAO certifications. Shipment by air remains the norm for small-molecule oncology APIs, given expiry dating and temperature assurance constraints. Payment terms strictly adhere to established credit vetting results—large contract partners may operate on 30-day net, but new contracts require advance payment or irrevocable L/C. Shipments follow Incoterms negotiated per agreement, never generalized.

Pricing Structure & Influencing Factors

Raw Material Cost Composition & Fluctuation Causes

Total API cost traces directly to the purity of starting substrates, solvent grade, chiral auxiliary demand, and catalyst lifecycle management. Tivozanib’s process route commonly employs high-cost intermediates with patent-encumbered supply streams; even marginal changes in global sources of protected intermediates or regulatory audits on key upstream suppliers provoke cost rebalancing. Critical trace impurity control steps increase purification overhead, especially for oncology grades, sharpening the base cost difference between registered and off-patent sourcing. Market events like regulatory crackdowns, supply interruptions of rare ligands, or volatility in magnesium, palladium, and high-purity acetonitrile drive price change.

Grade, Purity & Packaging Certification Impact

Grade specification dictates overall pricing: clinical trial, commercial API, and reference standard forms each pass through different validation, release, and batch documentation regimes. Typical price gaps arise between technical, GMP-intermediate, and final GMP API grades because of the added purification and full-spectrum analytical release required for patient-ready material. Purity, measured by both HPLC and chiral assay, affects both release success and overall yield, which translates to direct cost impact—higher purity orders use more resource-intensive purification and double the release analytics. Packaging with additional certification (such as UN certified, DMF supporting material, or country-specific stability addendums) will add incremental cost that aligns with compliance workload.

Global Market Analysis & Price Trends

Global Supply & Demand Overview

Current analysis indicates capacity closely tracks regulatory approvals in US, EU, and selectively Asia-Pacific. Volume surges stem from expanded oncology indications or lifecycle management entrants in the US and Europe. Japanese and Indian demand reflects local regulatory strategies, often tied to specific local manufacturing partnerships or contract manufacture for global supply.

Key Economies Analysis: US/EU/JP/IN/CN

US and EU buyers enforce the strictest release validation and batch traceability tests, especially post-vial recall events in recent years. Authorization variations between regions (e.g., if the same intermediate source is not globally registered) create temporary bottlenecks. Japan maintains preference for local audit, which influences preferred supply routes and adds to requalification testing. India plays a dual role both as a major consumer (through local production partnerships) and as a producer using alternative process routes that challenge cost baselines globally. China's participation focuses on intermediary or raw substrate provision, with recent regulatory tightening causing sudden price spikes where imports depend on a single upstream supplier cleared by their NMPA or US FDA.

2026 Price Trend Forecast

By 2026, price trends project moderate upward pressure. Market models consider global oncology demand, new therapy launches increasing base demand, and ongoing regulatory shifts targeting impurity minimisation. Regulatory inspections and data integrity demands in China and India complicate raw input availability. Patent cliffs and generic entry will start shifting risk as originator market exclusivity recedes, but oncologic drugs sitting on dual supplied intermediates limit the scope for heavy price correction. Expect spread between GMP and technical/non-GMP grades to widen with continued pharmacovigilance emphasis.

Data Sources & Methodology

All assessments reference recent production reports, procurement data, regulatory filings, and third-party raw input indices. We frequently validate cost impact assumptions against updated import-export records, active regulatory warning notices, and internal batch cost-control analyses.

Industry News & Regulatory Updates

Recent Market Developments

Market demand mapped a clear rise after expanded EU and US indications, but regulatory re-inspection waves post-2023 led to API supply interruptions due to enhanced nitrosamine review protocols. Dedicated lines for GMP oncology APIs saw fast-tracked investment as a direct response to new regulatory scrutiny, recutting available capacity for non-oncology contract campaigns.

Regulatory Compliance Updates

The latest regulatory guidance now expects lower detection limits for mutagenic impurities, with immediate reporting of all out-of-spec results and tighter documentation control. This directly impacts cycle time and raw material audit requirements within contract manufacturing workflows. Any non-conformance sends production back to root cause review, often delaying batch release and increasing working capital tied up in inventory. New US and EU GMP rules for oncology APIs restrict the pool of eligible suppliers, and only those with full traceability down to raw input origin now reach final commercial release.

Supplier Response & Mitigation

Manufacturers responded to heightened quality standards by advancing real-time batch analytics, doubling the process validation sample size, and enforcing stricter vendor qualification. Secondary and tertiary supplier qualification gained ground, but in-process deviations or intermediate shortages still create residual risk windows. Capacity reallocation between existing clients and new registrations has demanded week-to-week reevaluation at the production planning level. Technical teams oversee every step from route selection, raw input assay, impurity mapping, through to batch documentation, and use feedback from post-market vigilance reports to refine control point interventions.

Application Fields & Grade Matching Guide for FOTIVDA® (Tivozanib)

Industry Applications

FOTIVDA® (Tivozanib) finds its role across the biopharmaceutical industry, primarily in the manufacture of targeted oncology therapeutics. The compound targets vascular endothelial growth factor receptors and requires precise manufacturing and quality assurance standards, especially for pharmaceutical formulations intended for human therapy. Beyond clinical settings, Tivozanib may also support research applications in angiogenesis studies and oncology drug screening processes.

Grade-to-Application Mapping

Application Recommended Grade Key Industrial Rationale
Pharmaceutical Formulation (API use) Pharmaceutical Grade Selection centers on compliance with regulatory drug substance standards. Batch traceability and impurity profile management drive grade selection for clinical use.
Preclinical Research Research Grade Batch selection reflects the need for lower-volume, flexible packaging options, with focus on lot-to-lot consistency, yet without the full regulatory validation layer required for human administration.
Analytical Reference Analytical Standard Grade Analytical grade emphasizes ultra-purity and defined impurity thresholds tailored for assay calibration or QC method validation. Sourcing from validated lots with full documentation supports lab certification protocols.

Key Parameters by Application

For pharmaceutical applications, residual solvent content, specific optical purity, and validated impurity profiles determine final acceptance. Analytical and R&D settings may accept broader impurity spectra. Exact property windows are governed by regulatory filings, regional authority requirements, and endpoint use.

Pharmaceutical-grade Tivozanib undergoes stringent in-process and release testing focused on enantiomeric purity, water content by Karl Fischer titration, and confirmatory NMR and HPLC identity. Research and analytical grades often exhibit wider variability provided documentation supports intended use. Sensitivity to hydrolysis or oxidation during storage or handling varies based on grade-controlled formulation and packaging: pharmaceutical-grade packaging incorporates moisture and oxygen barriers, while research-grade may permit more flexible storage options.

Batch homogeneity, polymorphic form stability, and absence of process- or storage-derived impurities are maintained through process route selection and purification strategy adjustments for each grade.

How to Select the Right Grade of Tivozanib

Step 1: Define Application

Specify the end use: commercial API production, clinical supply, preclinical research, or analytical calibration. Each use requires distinct grade selection logic.

Step 2: Identify Regulatory Requirements

For clinical and commercial manufacturing, verify regional guidelines (FDA, EMA, etc.) and pharmacopoeial standards apply. Documentation for research or non-clinical applications may be less burdensome but still relies on robust batch records.

Step 3: Evaluate Purity Needs

Pharmaceutical applications demand tight control of single- and total-impurity content, specific optical isomer, and residual solvent bands. Research and analytical work may tolerate broader specifications provided stability and assay performance are unaffected.

Step 4: Consider Volume & Budget

Commercial manufacturing usually requires large-volume, contractually defined supplies; research or QC uses call for appropriate pack sizing, which affects manufacturing batch size and cost structure.

Step 5: Request Sample for Validation

Always request a representative sample under actual production conditions before full-scale order or project commitment. This allows on-site analytical and performance validation against customer-specific standards. Manufacturers track validation feedback to optimize batch consistency and address any in-field performance deviations.

Manufacturer’s Perspective on Production and Quality Control

Raw material sourcing prioritizes traceability, process route reproducibility, and precursor impurity control. Each route's critical points—solvent selection, key reaction or crystallization steps—define expected impurity patterns and guide selection of downstream purification technologies.

Process control relies on sequential in-process checks: intermediate purity, phase identification, and solvent profile. High-potency actives require closed-containment handling, particularly for pharmaceutical-grade production, to avoid cross-contamination and maintain operator safety. Batch consistency tracks directly to process automation and monitoring protocols.

Release criteria emerge from a mix of pharmacopeial monographs, regulatory guidelines, and end-user requirements, all aligned with lot release protocols, including retention sample archiving and documentation.

Trust & Compliance: Quality Certifications & Procurement Support for FOTIVDA® (Tivozanib)

Quality Compliance & Certifications

Quality Management Certifications

Manufacturing of FOTIVDA® (Tivozanib) takes place at a dedicated facility where quality management systems are built on internationally recognized frameworks. Certification under ISO 9001 forms the backbone of our plant’s quality system. This standard aligns daily operations, audits, and documentation with best practice protocols for pharmaceutical production. In practice, ISO 9001 guides regular review of corrective and preventative measures, traceability from raw material through release, and controls around change management. Inspection findings, regulatory agency audits, and internal reviews together inform how deviations are managed to reduce risk of nonconforming product lots reaching the supply chain.

Product-Specific Certifications

Tivozanib production follows Good Manufacturing Practice principles in line with both regional and international regulatory filing requirements. This includes regular site inspections, review and maintenance of validated process steps, and routine proficiency tests for analytical methods. Certificates of Analysis (CoA) support every released batch, listing the actual analytical values for designated quality attributes, from purity and assay through to individual impurity thresholds. Where regional authorities require product registration, such as with the US FDA, European Medicines Agency, or China NMPA, supporting documentation and inspections are updated as regulations evolve. Detailed release criteria remain application-specific and can be adjusted based on the destination market.

Documentation & Reports

Each batch comes with a comprehensive documentation package, aligning with both internal batch records and client needs in regulated markets. Typically, this includes CoA, process flowchart, raw material lot traceability, and where required, Certificates of Compliance (CoC) referencing the agreed specification. Registration-supporting dossiers can be provided for regulatory submissions or for customer Quality Agreements. Stability data and trending reports over multiple lots provide a longitudinal view of product consistency and process drift, subject to ongoing customer and auditor review.

Purchase Cooperation Instructions

Stable Production Capacity Supply and Flexible Business Cooperation Plan

Supply planning for Tivozanib integrates upstream capacity for key intermediates with forecasted demand from downstream partners. Production slots prioritize long-term supply contracts. Orders cover flexible delivery volumes, ranging from small clinical development lots to commercial scale, taking variance in demand cycles into account. Real-time capacity updates and mutual forecasting reviews are provided for partners managing dynamic inventory schedules.

Core Production Capacity and Stable Supply Capability

Manufacturing scale depends on batch design, equipment availability, and grade specification. Dedicated lines for oncology actives minimize risk of cross-contamination and maintain compliance with health authority requirements. Redundancy in raw material sourcing, availability of validated process intermediates, and warehouse-controlled climate zones all reduce the risk of supply disruption. Lot release is always contingent upon current quality control outcomes, and real capacity limits are communicated transparently during project kick-off.

Sample Application Process

Customers seeking evaluation samples of Tivozanib should initiate a formal application including intended use, requested amount, and relevant compliance documentation. Samples are drawn from commercial process lots, subjected to the same in-process control and batch release procedures as commercial quantities. Clients may request CoA, origin traceability, or tailored regulatory support documents as applicable to the stage of their development program.

Detailed Explanation of Flexible Cooperation Mode

Flexible contracting modes are available, including annual supply agreements, spot orders, and development-stage support packages. Terms can accommodate project-based confidential manufacturing, custom specification definitions, and rapid reallocation of available capacity across multiple therapeutic projects. Contract terms clarify lead time expectations, change notification protocols, minimum order requirements, and escalation procedures for urgent needs or deviation management. Partners working through regulatory harmonization phases receive dedicated support for tailored documentation and audit preparation.

Market Forecast & Technical Support System for FOTIVDA® (Tivozanib)

Research & Development Trends

Current R&D Hotspots

Tivozanib draws focused attention among vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors due to its high selectivity and manageable toxicity profile. Manufacturers monitor ongoing investigations targeting improved resistance profiles and combination regimens, especially where immune checkpoint inhibitors have changed treatment paradigms. Batch analysis from recent manufacturing cycles shows an uptick in orders tied to trial sites focusing on treatment-refractory disease and front-line settings. Process R&D teams must tailor particle size, impurity tracks, and solubility profiles for applications ranging from classic solid tumors to combination with emerging immunotherapies.

Emerging Applications

Clinical development initiates interest beyond renal cell carcinoma, with ongoing trials evaluating potential in rare vascularized tumors and as adjuncts in combination protocols. Where grade, particle morphology, and polymorph content influence formulation outcomes, process flexibility and specification-driven production adjustments remain critical. Customers investigating novel delivery formats often require adaptable micronization methods and discussion of carrier or excipient compatibility, which creates both new technical challenges and closer engagement through the technical support cycle.

Technical Challenges & Breakthroughs

Production lines report challenges holding impurity profiles within stricter clinical-phase boundaries due to high potency and narrow impurity allowances on drug substance. Consistent polymorph control remains a key focus; observed deviations typically link to upstream crystallization conditions, which require feedback loops between QC, production, and technical documentation. Recent improvements center on process analytics, with rapid in-line monitoring and data-driven adjustments to optimize yield without sacrificing specification compliance. These breakthroughs lower the risk of nonconforming batches in scale-up stages.

Future Outlook

Market Forecast (3-5 Years)

Based on direct order flows and confirmed expansion of clinical studies, manufacturers anticipate steady demand growth, with possible surges tied to approval of new indications and combination regimens. Peak demand periods often coincide with expansion waves at international trial sites. Planning raw material supply agreements and scheduling production slots in anticipation of trial expansion remain essential for timely batch release.

Technological Evolution

Manufacturing expertise continues to migrate toward advanced synthesis routes that reduce solvent consumption and minimize critical impurities. Vendors supplying key starting materials face more stringent traceability and impurity management demands. Secondary process technology—such as continuous flow systems and closed-loop solvent recovery—enable tighter in-process control. Teams are adapting release criteria for bioequivalence across generics and innovative protocols, making grade-focused dialogue fundamental to supporting new formats.

Sustainability & Green Chemistry

Raw material selection now factors in life cycle analysis, seeking routes that limit environmental persistence and hazardous waste output. Sourcing for solvents, reagents, and primary intermediates is shifting toward greener alternatives where technically feasible. Production units deploy solvent recycling on a growing share of campaigns; internal metrics compare environmental footprint per batch. Diverse regional regulations press for continuous improvement across waste management, effluent treatment, and emissions monitoring to support long-term manufacturing permits.

Technical Support & After-Sales Service

Technical Consultation

Technical teams include dedicated chemists and formulation experts prepared to address queries related to product grade, impurity profiles, and compatibility with customer-specific delivery platforms. Consultations may include support for method development, troubleshooting of crystallization anomalies, or transfer of technical documentation packages for regulatory filings.

Application Optimization Support

Support teams frequently work with customers' R&D to adjust batch attributes—such as particle size distribution and moisture limits—tailored to specific process or device integration requirements. In-process recommendations draw from manufacturing data, facilitating adjustment of blending parameters, dissolution testing, and downstream sterilization or filling protocols.

After-Sales Commitment

Post-shipment, manufacturer maintains batch traceability, retains parallel samples for root cause analysis, and supplies comprehensive change-control notifications. Ongoing stability studies use retained lots for comparative performance against evolving end-user requirements. Customers benefit from proactive updates on documentation, allowing seamless integration into updated regulatory filings or new development cycles. Teams conduct regular post-audit reviews to confirm continued compliance of released lots with market-specific pharmacopoeial and client-set acceptance criteria.

FOTIVDA® (Tivozanib): Reliable Production for Industrial and Commercial Demands

At our facility, we manufacture FOTIVDA® (Tivozanib) using precision-controlled processes developed over years of production refinement. All critical manufacturing steps, from synthesis through purification and final quality assessment, operate under direct supervision of senior technical staff. Industrial and commercial partners rely on this foundation for consistent output and repeatable performance. We maintain in-house expertise, so every batch receives direct oversight and hands-on attention throughout production.

Core Industrial Applications

Our FOTIVDA® serves as an essential API (active pharmaceutical ingredient) for pharmaceutical producers specializing in targeted oncology therapies. The compound supports drug formulation groups focused on advanced renal cell carcinoma and related applications. Formulators and process engineers count on FOTIVDA® purity and assay standards to keep development pipelines on track, especially under regulatory review. Each campaign receives tailored process adjustments to align with large-scale production requirements.

Maintaining Product Consistency and Quality Control

Stringent control procedures define the way we approach each order. Every lot undergoes robust analytical verification, including HPLC and impurity profiling. These checks happen on-site, using validated protocols and state-licensed equipment. Process chemists and QA analysts document results in detailed batch records, avoiding manual gaps or shortcuts. Annual facility audits and routine calibrations allow our teams to sustain batch-to-batch stability across extended manufacturing cycles.

Packaging and Supply Capability

Packaging lines handle both bulk and specialty formats to serve both clinical-scale and commercial production scales. Materials used for primary packaging meet pharmaceutical-grade standards, and every container is labeled with full traceability information, including batch, lot number, and production date. Rigorous sealing and secondary containment prevent cross-contamination and ensure safe transit from our plant to your loading dock. Large-scale warehousing supports buffer inventory, so we manage short delivery lead times for ongoing or urgent industrial usage.

Technical Support for Industrial Buyers

Direct communication with our scientists and production managers supports integration into customer processes. Technical data requests, process adaptation, and troubleshooting sit directly with our plant team—no intermediaries, no long wait times. Industrial buyers appreciate the practical answers and process guidance grounded in real equipment experience and historical performance data. This level of access supports faster onboarding for complex projects, reduces risks, and leads to successful regulatory filings on the customer side.

Business Value for Manufacturers, Distributors, and Procurement Teams

Procurement officers, supply chain managers, and industrial formulators recognize the value of working directly with a primary FOTIVDA® producer. By controlling production under our own roof, we maintain fixed pricing schedules and supply agreements that help avoid downstream disruption. Cost forecasting stays in line thanks to minimized uncertainty at the source. Distribution partners access authenticated shipments with verified documentation, which lowers the risk of counterfeits and meets the strict oversight from end-users and government agencies.

Long-term business agreements built with us translate to more stable supply pipelines and reduced operational headaches. Manufacturing partners can scale up programs with confidence in the technical and logistical backbone of every FOTIVDA® order. Each delivery results from our integrated quality, engineering, packaging, and logistics infrastructure working in coordination—eliminating handoffs and miscommunication that often occur outside the primary manufacturing channel.

Industrial FAQ

What is the mechanism of action and primary indication for FOTIVDA® (Tivozanib)?

Our Insights as the Manufacturer

Developing cancer therapeutics demands rigorous investment in research, process development, and ongoing quality control. FOTIVDA® (tivozanib) is one of the targeted therapies we produce through advanced synthetic routes validated for regulatory and industrial consistency. The way this molecule works directly relates to its chemical design, purpose-built to block specific cellular signals in cancer growth. We have dedicated years into improving yield, purity, and reproducibility in every batch, as the mechanism of tivozanib calls for reliability at the highest standard.

Mechanism of Action: Precision VEGF Receptor Inhibition

Tivozanib targets the vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. These receptors control key signals that drive blood vessel formation—angiogenesis—required by tumors for sustained growth. By blocking activity at these sites, tivozanib curbs new vessel formation around tumors, essentially starving the cancer cells. Our chemists understand the significance of selectivity in kinase inhibition. Tivozanib exhibits high specificity in our preclinical characterization, sharply reducing off-target effects common with poorly selective kinase inhibitors.

We design tivozanib for oral administration, and emphasize the reproducibility of absorption characteristics throughout our batches. Once absorbed, the compound interacts with VEGF receptors at the cell membrane, impeding downstream signaling cascades like MAPK and PI3K/AKT. Suppression of these pathways limits both vascular proliferation and permeability around the tumor. This mechanism supports a manageable toxicity profile for carefully selected patients, which our product consistency backs up with each production run.

Primary Indication: Advanced Renal Cell Carcinoma

Tivozanib has been examined and approved for use in patients with advanced renal cell carcinoma (RCC). In this indication, many individuals have either undergone prior treatments or are unsuitable for traditional lines of therapy. Tumor cells in RCC frequently exploit VEGF-driven angiogenesis for expansion, creating a clinical need for highly targeted therapies. Our team developed tivozanib to fit the specific pathophysiology of RCC where VEGF pathway dependency is documented.

We produce FOTIVDA® to meet stringent regulatory expectations for oncology products. The stability data, analytical validation, and process controls address the exacting requirements set by oncologists treating patients in this critical stage. By maintaining a long half-life and potent inhibitory profile, tivozanib stays effective as a once-daily oral therapy—an aspect which has meaningful impact for patients managing complex treatment regimens.

Manufacturing Considerations and Solutions

Meeting the clinical demands for FOTIVDA® means sustaining supply chain integrity and product homogeneity over extended campaigns. Our technical team controls every facet of production, from raw material sourcing through to finished product release, using validated analytical techniques to ensure consistency between lots. We stay focused on minimizing impurities and maximizing recovery at scale, providing confidence both to health care providers and regulatory reviewers.

As direct manufacturers, we can provide comprehensive quality and batch records on request. We also dedicate resources to further understanding metabolic stability and exploring new indications in solid tumors where VEGF signaling is implicated. Stakeholders—including clinicians and researchers—have direct access to our technical department for data-sharing or process clarifications. This open-door policy stems from our responsibility as developers, not simply suppliers, of advanced chemical agents intended for real-world patient use.

Our focus remains on controlled, reproducible, and safe production of tivozanib, effectively supporting the medical teams and patients who rely on its benefits for advanced renal cell cancer.

What are the available package sizes and pricing details for procurement of FOTIVDA® (Tivozanib)?

Our facility manufactures FOTIVDA® (Tivozanib) with strict quality assurance throughout the entire production chain. This commitment extends from sourcing of key starting materials to final packaging operations, as we understand the critical importance of traceability and product authenticity in oncology therapeutics. Our standard packaging for Tivozanib tablets follows rigorous containment, lot tracking, and GMP-certified protocols.

Available Package Sizes

For clinical and commercial supply, we offer Tivozanib in standardized formats that address both hospital demand and specialty oncology pharmacy channels. Our typical commercial pack contains Tivozanib oral tablets at a strength of 1.34 mg. Each carton provides a 21-count blister for direct dispensing, which reflects patient dosing cycles and improves stock management within hospital pharmacies and cancer treatment centers. These 21-tablet blisters serve daily administration for a cycle-based regimen, which many physicians prescribe in accordance with product labeling and treatment protocols.

Bulk procurement options support clinical research organizations and specialty distribution networks for larger-scale, non-retail use. Upon request, the technical division can supply specifications for alternative bulk formats—up to multi-carton cases, meeting regulatory and logistical requirements in key markets. We maintain packaging traceability to minimize risk of diversion or substitution, especially during direct-to-site shipments. Every format uses anti-tamper features and serialized barcodes for product authentication according to current regulatory guidance.

Pricing Details from the Manufacturer

Pricing for FOTIVDA® is a complex subject because we factor in several operational and regulatory considerations. From an industrial production standpoint, Tivozanib’s cost structure accounts for the raw material supply chain, precision synthesis technology, quality control testing, and packaging investments. We review volume tiers for institutional buyers, integrated group purchasing organizations, and authorized specialty pharmacies. As manufacturer, we set base ex-factory prices for authorized purchasers in alignment with official price notifications, where required by law, and negotiate contract pricing for long-term supply partnerships.

Most inquiries relate to direct ex-manufacturing rates, which do not include ancillary distributor markups or downstream logistics fees. As such, the ex-manufacturer price for each pack reflects current production costs, regulatory fees, and logistical overhead incurred until release from our licensed site. We routinely conduct pricing reviews to ensure transparency. Our commercial team can engage in volume-based pricing discussions subject to anti-diversion policies and institutional risk management. For single clinical packs, the price may be higher due to additional small-lot fulfillment costs compared to multi-carton bulk orders for hospitals or cancer centers.

We understand that budgetary certainty and reimbursement forecasting play significant roles for formulary managers and hospital procurement officers. The technical and sales teams work directly with authorized customers to provide up-to-date price lists, support tender applications, and develop managed access programs. We can provide a statement of origin and batch-level quality documentation as part of any contract pack or bulk order agreement.

Supporting Sustainable Oncology Access

As global demand for oral oncolytics increases, our manufacturing planning prioritizes on-time release and product integrity across all package sizes and markets served. Our facility remains committed to uninterrupted supply, adapting batch scales as needed to meet evolving national guidelines and procurement cycles. Customers receive factory-direct support, from pre-tender technical queries to post-shipment product stewardship and pharmacovigilance collaboration. Through direct engagement, we ensure the security, reliability, and traceable origin of every pack that leaves our production facility.

Are there any specific storage, handling, or regulatory compliance requirements for shipping and storing FOTIVDA® (Tivozanib)?

Producing FOTIVDA® (Tivozanib) at commercial scale involves a chain of precise steps, from synthesis to distribution. The integrity of this medication depends not only on formulation but also on prudent precautions during storage and shipment. In our production facilities, we developed comprehensive protocols rooted in real-world experience and regulatory guidance to ensure that every unit shipped maintains safety and performance throughout the supply chain.

Storage Considerations

FOTIVDA® tablets remain stable under conditions that avoid direct sunlight, elevated temperature, and ambient moisture. We qualify our warehouses and logistics centers for controlled temperature, holding stock at routine room temperature as specified by regulatory filings. Our technical team established periodic checks and automated alarms to catch fluctuations, as stability data show the product tolerates limited excursions but chronic exposure above prescribed limits undermines product quality. Cardboard cartons and sealed blister packaging further guard against incidental humidity and physical damage. In practical applications, we have observed that such measures allow cartons to withstand standard shipping stresses without risk of breakage or environmental intrusion.

Handling Controls Within Production and Shipping

We mark our product cartons with clear “store below 25°C” and “protect from light” icons to reduce risk during warehouse transitions or transfer unloading. Our shipping department uses temperature mapping to assess vehicle compartments, selecting methods suitable for the size of consignment. For domestic transit, ambient van shipments align with our validated temperature range. For exports passing through unpredictable customs delays or extreme climates, we specify temperature-monitoring tags, and, when warranted by route analysis, insulated boxing or gel packs. Over the last several years, we have tracked batch lots point-to-point in the rare event of a deviation, issuing corrective actions and maintaining documentation for full traceability.

Regulatory Compliance and Documentation

Compliance with Good Distribution Practice (GDP) for medicinal products drives all our logistics steps. We maintain audited agreements and routine training with warehouse and transport partners. Every outgoing batch ships with a certificate of analysis referencing conformity, and our quality assurance team retains full batch documentation for years post-expiry in accordance with regulatory guidance. In regions requiring import licenses or prior notifications for finished pharmaceutical products, our regulatory affairs staff coordinates directly with recipients to clear inbound shipments efficiently and avoid detention. In our experience, close alignment between production, quality, and shipping departments keeps us prepared to answer regulators’ questions or investigate anomalies before they can impact downstream supply.

Risk Awareness and Practical Solutions

Temperature excursions in transit pose the most common risk for oral kinase inhibitors such as Tivozanib. Our technical staff review all monitoring logs upon receiving customer feedback or adverse storage reports. We use root cause investigations rather than prescriptive paperwork to tune our procedures to actual practice and keep failure rates to a minimum. We apply the same data-driven vigilance to handling expired stock returns, ensuring proper containment and disposal methods that meet environmental and safety expectations. This approach upholds our responsibilities to both our direct customers and the patients relying on FOTIVDA® for ongoing therapy.

Reliable supply of sensitive pharmaceuticals calls for more than regulatory box-ticking. Our on-floor teams bring operational discipline informed by years of commercial shipment experience, preserving trust and product quality through every step of the chain. We keep storage, shipping, and compliance practical, data-based, and responsive—ensuring FOTIVDA® reaches physicians and patients safely, batch after batch.

Technical Support & Inquiry

For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales6@ascent-chem.com, +8618018036652 or WhatsApp: +8618018036652